Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2571-2579

  Kasono, Keizo ^a   Blackwell, Jerry L ^a   Douglas, Joanne T ^a   Dmitriev, Igor ^a   Strong, Theresa V ^a   Reynolds, Paul ^a   Kropf, David A ^b   Carroll, William R ^b   Peters, Glenn E ^b   Bucy, R Pat ^a   Curiel, David T ^a   Krasnykh, Victor ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOVIRIDAE; CARCINOMA, SQUAMOUS CELL; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HELA CELLS; HUMANS; INTEGRIN ALPHA3BETA1; INTEGRINS; OLIGOPEPTIDES; RECEPTORS, COLLAGEN; RECEPTORS, VIRUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0032835001     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Clayman, G. L. Gene therapy for head and neck cancer. Head Neck, 17: 535-541, 1995.
2. Van Dongen, G. A., and Snow, G. B. Prospects for future studies in head and neck cancer. Eur. J. Surg. Oncol., 23: 486-491, 1997.
3. Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., and Hong, W. K. Head and neck cancer. N. Eng. J. Med., 328: 184-191, 1993.
4. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin., 45: 8-30, 1995.
5. Von Hoff, D. D., Head and neck cancer. In: J. H. Stein (ed.), Internal Medicine, pp. 943-947. New York: Mosby-Year Book, 1994.
6. Ervin, T. J., Clark, J. R., Weichselbaum, R. R., Fallon, B. G., Miller, D., Fabian, R. L., Posner, M. R., Norris, C. M., Jr., Tuttle, S. A., and Schoenfeld, D. A. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J. Clin. Oncol., 5: 10-20, 1987.
7. Clayman, G. L., El-Nagger, A. K., Roth, J. A., Zhang, W. W., Goepfert, H., Taylor, D. L., and Liu, T. J. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous cell carcinoma. Cancer Res., 55: 1-6, 1995.
8. O'Malley, B. W., Jr., Chen, S. H., Schwartz, M. R., and Woo, S. L. C. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res., 55: 1080-1085, 1995.
9. Liu, T. J., el-Nagger, A. K., McDonnel, T. J., Steck, K. D., Wang, M., Taylor, D. L., and Clayman, G. L. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res., 55: 3117-3122, 1995.
10. Wilson, K. M., Stambrook, P. J., Bi, W. L., Pavelic, Z. P., Pavelic, L., and Gluckman, J. L. HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect. Arch. Otolaryngol. Head Neck Surg., 122: 746-749, 1996.
11. Takahashi, T., Carbone, D., Takahashi, T., Nau, M. M., Hida, T., Linnoila, I., Ueda, R., and Minna, J. D. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res., 52: 2340-2343, 1992.
12. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
13. Austin, E. A., and Huber, B. E. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol., 43: 380-338, 1993.
14. Mullen, C. A. Metabolic suicide genes in gene therapy. Pharmacol. Ther., 63: 199-207, 1994.
15. Goebel, E. A., Davidson, B. L., Zabner, J., Graham, S. M., and Kern, J. A. Adenovirus-mediated gene therapy for head and neck squamous cell carcinomas. Ann. Otol. Rhinol. Laryngol., 105: 562-567, 1996.
16. Sewell, D. A., Li, D., Duan, L., Schwartz, M. R., and O'Malley, B. W., Jr. Optimizing suicide gene therapy for head and neck cancer. Laryngoscope, 107: 1490-1495, 1997.
17. Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., and Finberg, R. W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (Washington DC), 275: 1320-1323, 1997.
18. Miller, R. M., Buchsbaum, D. J., Reynolds, P. N., Douglas, J. T., Gillespie, G. Y., Mayo, M. S., Raben, D., and Curiel, D. T. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res., 58: 5738-5748, 1998.
19. Navarro, J. G., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. Gene therapy; ovarian carcinoma as the paradigm. Am. J. Clin. Pathol., 109: 444-467, 1998.
20. Simon, R. H., Engelhardt, J. F., Yang, Y., Zepeda, M., Weber-Pendleton, S., Grossman, M., and Wilson, J. M. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum. Gene Ther., 4: 771-780, 1993.
21. Bout, A., Imler, J. L. Schultz, H., Perricaudet, M., Zurcher, C., Herbrink, P., Valerio, D., and Pavirani, A. A. In vivo adenovirus-mediated transfer of human CFTR cDNA to rhesus monkey airway epithelium: efficacy, toxicity and safety. Gene Ther., 1: 385-394, 1994.
22. Douglas, J. T., and Curiel, D. T. Adenoviruses as vectors for gene therapy. Science and Medicine, 4: 44-53, 1997.
23. Goldman, C. K., Rogers, B. E., Douglas, J. T., Sosnowski, B. A., Ying, W., Siegal, J. P. Baird, A., Campain, J. A., and Curiel, D. T. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res., 57: 1447-1451, 1997.
24. Douglas, J. T., Rogers, B. E., Rosenfeld, M. E., Michael, S. I., Feng, M., and Curiel, D. T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotech., 14: 1574-1578, 1996.
25. Michael, S. I., Hong, J. S., Curiel, D. T., and Engler, J. A. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther., 2: 660-668, 1995.
26. Krasnykh, V., Dmitriev, I., Mikheeva, G., Miller, C. R., Belousova, N., and Curiel, D. T. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol., 72: 1844-1852, 1998.
27. Dmitriev, I., Krasnykh, V., Miller, C. R., Wang, M., Kashentseva, E., Mikheeva, G., Belousova, N., and Curiel, D. T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackie and adenovirus receptor-independent cell-entry mechanism. J. Virol., 72: 9706-9713, 1998.
28. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36: 59-74, 1977.
29. Herz, J., and Gerard, R. Adenovirus-mediated transfer of low-density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA, 90: 2812-2816, 1993.
30. Graham, F., and Prevec, L. Manipulation of adenovirus vectors. In: E. J. Morray and J. M. Walker (eds.), Methods in Molecular Biology, Vol. 7, pp. 109-129. Clifton, NJ: Humana Press, 1991.
31. Hsu, K. H., Lonberg-Holm, K., Alstein, B., and Crowell, R. L. A monoclonal antibody specific for the cellular receptor for the group B Coxsackie viruses. J. Virol., 62: 1647-1652, 1988.
32. Krasnykh, V. N., Mikheeva, G. V., Douglas, J. T., and Curiel, D. T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol., 70: 6839-6846, 1996.
33. Bucy P., Panoskaltsis-Mortari, A., Huang, G., Li, J., Karr, L., Ross, M., Russell, J. H., Murphy, K. M., and Weaver, C. T. Heterogeneity of single cell cytokine gene expression in clonal T cell populations. J. Exp. Med., 180: 1251-1262, 1994.
34. Panoskaltsis-Mortari, A., and Bucy B. In situ hybridization with digoxigenin-labeled RNA probes: facts and artifacts. BioTechniques, 18: 300-307, 1995.
35. Huber, B. E., and Lazo, J. S. (eds). Gene therapy for neoplastic diseases. Ann. N. Y. Acad. Sci., 716: 1994.
36. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst., 89: 21-39, 1997.
37. Belin, M. T., and Boulanger, P. Involvement of cellular adhesion sequences in the attachment of adenovirus to the HeLa cell surface. J. Gen. Virol., 74: 1485-1497, 1993.
38. 5 promote adenovirus internalization but not virus attachment. Cell, 73: 309-319, 1993.
39. 5 selectively promotes adenovirus mediated cell membrane permeabilization. J. Cell Biol., 127: 257-264, 1994.
40. 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J. Virol., 69: 2257-2263, 1995.
41. Hesdorffer, C., Ayello, J., Ward, M., Kaubisch, A., Vahdat, L., Balmaceda, C., Garrett, T., Fetell, M., Reiss, R., Bank, A., et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J. Clin. Oncol., 16: 165-172, 1988.
42. Bellon, G., Michel-Calemard, L., Thouvenot, D., Jagneaux, V., Poitevin, F., Malcus, C., Accart, N., Layani, M. P., Aymard, M., Bernon, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a Phase I clinical trial. Hum. Gene Ther., 8: 15-25, 1997.
43. Waes, C. V. Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Head Neck, 17: 140-147, 1995.
44. Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol., 12: 697-715, 1996.
45. Hynes, R. O. Integrins: a family of cell surface receptors. Cell, 48: 549-550, 1987.
46. Hynes, R. O. Integrins: versatility, modulation and signaling in cell adhesion. Cell, 69: 11-25, 1987.
47. 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J. Cell Biol., 113: 919-929, 1991.
48. Douglas, J. T., and Curiel, D. T. Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenovirus vectors. Neuromuscul. Disord., 7: 284-298, 1997.